Patents by Inventor Janusz J. Kulagowski
Janusz J. Kulagowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160051531Abstract: The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: ApplicationFiled: March 24, 2015Publication date: February 25, 2016Inventors: Hazel J. Dyke, Susan M. Cramp, Thomas D. Pallin, Janusz J. Kulagowski, John G. Montana, Robert Zahler
-
Patent number: 9067905Abstract: The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: GrantFiled: April 23, 2012Date of Patent: June 30, 2015Assignee: Zafgen, Inc.Inventors: Hazel J. Dyke, Susan M. Cramp, Thomas D. Pallin, Janusz J. Kulagowski, John G. Montana, Robert Zahler
-
Publication number: 20130053364Abstract: The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: ApplicationFiled: April 23, 2012Publication date: February 28, 2013Inventors: Hazel J. Dyke, Susan M. Cramp, Thomas D. Pallin, Janusz J. Kulagowski, John G. Montana, Robert Zahler
-
Patent number: 5622950Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: June 2, 1995Date of Patent: April 22, 1997Assignee: Merck, Sharp & Dohme Ltd.Inventors: Raymond Baker, Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
-
Patent number: 5607946Abstract: A class of chemical compounds comprising a 2(1H)-quinolone moiety and a substituted heterocyclic moiety, linked via the 3-position of the 2(1H)-quinolone moiety by a methylene group, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: August 30, 1995Date of Patent: March 4, 1997Assignee: Merck Sharp & Dohme Ltd.Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
-
Patent number: 5576336Abstract: Compounds of formula (I), or a salt or prodrug thereof, wherein R represent hydrogen or C.sub.1-6 alkyl; Q represents a moiety of formula Qa or Qb; they are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: September 13, 1995Date of Patent: November 19, 1996Assignee: Merck Sharp & Dohme LimitedInventors: Raymond Baker, Howard B. Broughton, Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
-
Patent number: 5576319Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: August 26, 1994Date of Patent: November 19, 1996Assignee: Merck, Sharp & Dohme Ltd.Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
-
Patent number: 5563150Abstract: A class of chemical compounds comprising a pyrrolo[2,3-b]pyridine moiety and a halo-substituted heterocyclic moiety, linked via the 3-position of the pyrrolo[2,3-b]pyridine moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.Type: GrantFiled: August 9, 1995Date of Patent: October 8, 1996Assignee: Merck, Sharp & Dohme Ltd.Inventors: Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson
-
Patent number: 5563152Abstract: A class of chemical compounds comprising a pyrrolo[2,3-b]pyridine moiety and a carboxamido-substituted heterocyclic moiety, linked via the 3-position of the pyrrolo[2,3-b]pyridine moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.Type: GrantFiled: August 9, 1995Date of Patent: October 8, 1996Assignee: Merck, Sharp & Dohme Ltd.Inventors: Janusz J. Kulagowski, Paul D. Leeson
-
Patent number: 5559125Abstract: A class of 4-hydroxy-2-(1H)-quinolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.Type: GrantFiled: July 11, 1994Date of Patent: September 24, 1996Assignee: Merck, Sharp & Dohme LimitedInventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer, Michael Rowley
-
Patent number: 5432177Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.Type: GrantFiled: February 22, 1994Date of Patent: July 11, 1995Assignee: Merck Sharpe & Dohme Ltd.Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill
-
Patent number: 5426106Abstract: A class of 4-hydroxy-pyrrolo[1,2-b]pyridazin-2(1H)-one derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.Type: GrantFiled: March 16, 1993Date of Patent: June 20, 1995Assignee: Merck Sharp & Dohme LimitedInventors: Janusz J. Kulagowski, Paul D. Leeson
-
Patent number: 5420155Abstract: A class of 4-hydroxy-2(1H)-pyrrolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.Type: GrantFiled: May 10, 1993Date of Patent: May 30, 1995Assignee: Merck Sharp & Dohme Ltd.Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
-
Patent number: 5348962Abstract: This present invention relates to a class of 4-hydroxy-2-(1H)-quinolones which are substituted in the 3-position by an optionally substituted aryl substituent. These compounds are selective non-competitive antagonists of N-methyl-D-aspartate (NMDA) receptors.Type: GrantFiled: November 18, 1993Date of Patent: September 20, 1994Assignee: Merck Sharpe & Dohme Ltd.Inventors: Janusz J. Kulagowski, Ian M. Mawer, Paul D. Leeson, Michael Rowley
-
Patent number: 5346906Abstract: Pyridines, substituted by a quinuclidine and a substituent of low lipophilicity or a hydrocarbon substituent, their salts and prodrugs, and formulations thereof are useful in the treatment of neurodegenerative disorders such as dementia. The compounds can be synthesized by methods analogous to these known in the art.Type: GrantFiled: November 16, 1992Date of Patent: September 13, 1994Assignee: Merck Sharpe & Dohme Ltd.Inventors: Raymond Baker, John Saunders, Timothy M. Willson, Janusz J. Kulagowski